Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

NCT01518244 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma

Interventions

DRUG: Brinzolamide/timolol maleate fixed combination

Sponsor

Alcon Research